Alpha Teknova, Inc. (NASDAQ:TKNO - Get Free Report) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 1,660,000 shares, an increase of 72.2% from the February 13th total of 964,000 shares. Currently, 15.7% of the company's stock are short sold. Based on an average daily volume of 319,200 shares, the days-to-cover ratio is presently 5.2 days.
Analyst Ratings Changes
Separately, Craig Hallum started coverage on shares of Alpha Teknova in a research note on Monday, February 10th. They set a "buy" rating and a $12.00 price target for the company.
Check Out Our Latest Stock Analysis on TKNO
Hedge Funds Weigh In On Alpha Teknova
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC grew its stake in shares of Alpha Teknova by 8.4% in the fourth quarter. Squarepoint Ops LLC now owns 30,985 shares of the company's stock valued at $259,000 after buying an additional 2,388 shares in the last quarter. Two Sigma Investments LP lifted its holdings in Alpha Teknova by 46.2% during the 4th quarter. Two Sigma Investments LP now owns 15,148 shares of the company's stock valued at $126,000 after purchasing an additional 4,789 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Alpha Teknova during the 4th quarter valued at $335,000. Bank of America Corp DE lifted its holdings in Alpha Teknova by 1.8% during the 4th quarter. Bank of America Corp DE now owns 221,285 shares of the company's stock valued at $1,848,000 after purchasing an additional 3,904 shares during the last quarter. Finally, 683 Capital Management LLC acquired a new stake in Alpha Teknova during the 4th quarter valued at $744,000. 13.81% of the stock is owned by institutional investors.
Alpha Teknova Stock Down 0.5 %
Shares of TKNO traded down $0.03 during mid-day trading on Tuesday, hitting $5.62. 142,273 shares of the company's stock were exchanged, compared to its average volume of 302,923. The company has a market cap of $300.32 million, a PE ratio of -7.59 and a beta of 0.41. Alpha Teknova has a 52 week low of $1.16 and a 52 week high of $10.37. The company has a 50-day simple moving average of $7.73 and a 200 day simple moving average of $6.94. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 3.94.
Alpha Teknova (NASDAQ:TKNO - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.11) earnings per share for the quarter. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. The firm had revenue of $9.27 million during the quarter, compared to the consensus estimate of $9.10 million. On average, research analysts forecast that Alpha Teknova will post -0.58 earnings per share for the current fiscal year.
Alpha Teknova Company Profile
(
Get Free Report)
Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Featured Stories
Before you consider Alpha Teknova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Teknova wasn't on the list.
While Alpha Teknova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.